Loading organizations...
ReShape Lifesciences develops medical technologies for bariatric and rehabilitation. It offers minimally invasive devices for obesity management, like the Lap-Band® 2.0 FLEX system and Obalon balloon. The company also provides STIMEL-03®, an FDA-cleared rehabilitation technology for neuromuscular recovery post-stroke, aiming for advanced care and improved outcomes.
The company originated in 2002 as ReShape Medical, Inc., founded by Andrew Cragg. Cragg’s insight focused on non-surgical devices for obesity treatment, establishing a less invasive approach to weight management. This emphasis enabled its subsequent expansion into a broader medical device portfolio.
ReShape Lifesciences primarily serves patients with obesity and those needing neuromuscular rehabilitation, like stroke patients. Its vision is to advance therapeutic options by creating innovations that expand access to advanced medical interventions. The company strives to design effective technologies, enhancing quality of life for individuals facing health challenges.
ReShape Lifesciences has raised $3.0M across 1 funding round.
ReShape Lifesciences has raised $3.0M in total across 1 funding round.
ReShape Lifesciences has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series A in August 2007.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2007 | $3M Series A | — | 4See Ventures, NEW Leaf Venture Partners, Casey Tansey | Announced |
ReShape Lifesciences Inc. is a physician-led medical device company developing minimally invasive technologies and services to treat obesity and metabolic diseases, serving patients seeking alternatives to invasive bariatric surgeries like gastric bypass or sleeve gastrectomy.[1][2][3] Its core products include the Lap-Band (an adjustable gastric band for long-term weight loss), ReShape Vest System (an investigational laparoscopic device that wraps the stomach to reduce volume), Obalon Balloon System (for adults with BMI 30-40), and ReShapeCare (a virtual telehealth coaching program for sustained lifestyle changes).[1][3][4] The company addresses the global obesity epidemic by offering patient-friendly, non-anatomy-altering options backed by clinical evidence, with recent growth shown in Q3 2024 revenue up 16.6% sequentially and 6.4% year-over-year.[2]
Founded in 2002, ReShape Lifesciences initially focused on minimally invasive obesity treatments, evolving through mergers like the 2019 combination with Obalon Therapeutics, after which Obalon was renamed ReShape Lifesciences Inc.[1][2] The company went public via IPO in 2016 and is headquartered in Irvine, California (with early roots in San Clemente), employing about 47 people.[2][3] Pivotal moments include establishing a global Scientific Advisory Board in early 2023 to guide evidence-based growth and product development, alongside a history of over 1 million Lap-Band implants worldwide, building on 25 years of clinical data.[1][4]
ReShape Lifesciences rides the surging demand for obesity treatments amid rising global rates of metabolic disease, fueled by GLP-1 drugs like semaglutide but addressing gaps in durable, non-pharmacological options.[1][3] Timing aligns with post-pandemic health awareness and insurance expansions for bariatric alternatives, positioning minimally invasive devices as scalable bridges between meds and surgery in a market projected to grow with aging populations and tech-enabled telehealth.[2][4] It influences the ecosystem by pioneering physician-endorsed programs that integrate virtual coaching, potentially expanding access via reimbursements and collaborations, while competing in a fragmented space of device makers and digital health platforms.[1][4]
ReShape's momentum—marked by three straight quarters of revenue growth and new product pipelines—signals potential acceleration through R&D, M&A, and evidence expansion via its Scientific Advisory Board.[1][2] Trends like hybrid device-digital therapies and personalized metabolic care will shape its path, possibly amplifying influence if it captures share from surgical dominance amid GLP-1 evolution. Watch for commercialization wins with ReShape Vest and global Lap-Band scaling, tying back to its core as a differentiated obesity innovator.[1][3]
ReShape Lifesciences has raised $3.0M in total across 1 funding round.
ReShape Lifesciences's investors include 4See Ventures, New Leaf Venture Partners, Casey Tansey.
